甲状腺髓样癌靶向治疗新进展  

Research progress of targeted therapy in medullary thyroid carcinoma

作　　者：柴红[1] 陈泽泉[1] 余永利[1] 

机构地区：[1]上海交通大学附属第六人民医院核医学科,上海200233

出　　处：《上海交通大学学报（医学版）》2011年第10期1470-1474,共5页Journal of Shanghai Jiao tong University:Medical Science

摘　　要：对于晚期手术无法完整切除,且常规放化疗无效的甲状腺髓样癌(MTC)通常缺乏有效地治疗手段。靶向治疗是近年来在治疗血液和实体肿瘤中涌现出的新的治疗手段。随着对肿瘤发生、发展和转移的分子生物学机制深入,这种治疗手段也被用于MTC的治疗研究。目前用于MTC的主要药物包括小分子多靶点酪氨酸激酶抑制剂、血管内皮生长因子受体抑制剂和放射性核素靶向治疗药物,这些药物在基础研究、动物实验和临床实用研究中获得令人鼓舞的结果。其他药物如内皮生长因子受体(EGFR)酪氨酸激酶抑制剂吉非替尼(Gefitinib,ZD1839)、吲哚美辛和17烯丙胺17脱甲氧格尔徳霉素(17-AAG)等,在治疗晚期甲状腺髓样癌的临床试验中也显示出良好的前景。Advanced medullary thyroid carcinoma(MTC),which can not be completely resected and is null to conventional radiochemotherapy,usually lacks in effective strategies.Targeted therapy has emerged as a new strategy in the treatment of hematological and solid neoplasms.With the research progress of molecular biology mechanism on carcinogenesis,progression and metastasis,targeted therapy has been used in the research of treatment of MTC.The main drugs used in the treatment of MTC now include small molecule multiple tyrosine kinase inhibitor,vascular endothelial growth factor receptor inhibitor and radioactive nuclide targeted therapy medicine,all of which have yielded promising results in basic researches,animal experiments and clinical applications.The other drugs,such as endothelial growth factor receptor tyrosine kinase inhibitor Gefitinib(ZD1839),indometacin and 17 allylamino 17 demethoxygeldanamycin(17AAG),have also exhibited favorable prospects in the clinical trials of treatment of advanced MTC.

关 键 词：甲状腺髓样癌 靶向治疗 信号通路 

分 类 号：R736.1[医药卫生—肿瘤]